Cencora, Inc. First Quarter Fiscal 2026 Earnings Call February 4, 2026 Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," ...

Group 1 - Cardinal Health, Inc. (NYSE:CAH) is recognized as one of the 20 Best Performing Dividend Stocks in 2025, indicating strong market performance and investor confidence [1] - The company has shifted its focus towards higher-margin areas such as specialty pharmaceuticals and managed services, resulting in significant earnings growth, with forecasts estimating a growth of 19.3% in FY 2026 and 12.6% in FY 2027 [2] - The current payout ratio for dividends is at a modest 30.6%, providing the company with flexibility to potentially increase returns to shareholders in the future [3] Group 2 - Cardinal Health has raised its fiscal 2026 outlook, now expecting adjusted earnings per share between $9.65 and $9.85, an increase from the previous range of $9.30 to $9.50, reflecting a strong first-quarter performance [4] - The forecast includes contributions from the pending acquisition of Solaris Health, expected to close in early November, which may further enhance the company's growth prospects [4] - Cardinal Health operates as a global healthcare company, involved in the distribution of pharmaceuticals and medical products, manufacturing medical supplies, and providing various healthcare services [5]

Group 1: Cardinal Health - Cardinal Health's share prices have surged nearly 74% year to date, with significant gains following a strong quarterly earnings report [3][4] - Fiscal first-quarter 2026 revenue reached $64 billion, a 22% increase from the previous year, exceeding analyst expectations [3][5] - Adjusted earnings per share (EPS) of $2.55 surpassed Wall Street's forecasts, with estimates predicting EPS growth of 19% and 12.6% for the current and next fiscal years, respectively [5] Group 2: Loews - Loews shares have increased by 24% year to date, reflecting a turnaround from weak returns in the 2010s [6][8] - The company, controlled by the Tisch family, focuses on increasing intrinsic value per share and is actively repurchasing shares [9] - Loews owns significant stakes in CNA Financial and has interests in energy pipelines, hotels, and packaging, making it an attractive option for conservative investors seeking steady returns [8][9] Group 3: SanDisk - SanDisk's shares have surged over sixfold since splitting from Western Digital in February, with a 70% increase in the past month [10][11] - The company benefits from a NAND shortage, with robust demand for memory chips driven by artificial intelligence infrastructure [10] - SanDisk has raised NAND flash contract prices by 50%, and the market currently values its shares at a forward price-to-earnings (P/E) ratio of around 19, indicating potential for continued growth [10][12]

Financial Data and Key Metrics Changes - The company has increased its EPS guidance to a range of $15.85 to $16, reflecting strong performance throughout fiscal year 2025 [8] - The U.S. Healthcare Solutions segment has been a significant driver of growth, contributing to broad-based strong growth across the U.S. business [7][10] Business Line Data and Key Metrics Changes - Specialty pharmaceuticals have been identified as a key growth driver, with a focus on strengthening the company's position in this market [3][7] - The company has seen strong utilization trends and growth in sales of specialty products to physician practices and health systems [10] Market Data and Key Metrics Changes - The international segment, which accounts for 15% of operating income, has faced challenges, particularly in the global specialty logistics and consulting businesses [61][63] - There is an expectation of improved performance in the international business for fiscal year 2026 due to a rebound in clinical trial activity [66] Company Strategy and Development Direction - The company has outlined three growth priorities: leading with market leaders, strengthening its position in specialty markets, and enhancing patient access to pharmaceuticals [2][4] - Four strategic drivers have been identified: digital transformation, growth-oriented investments, productivity improvements, and talent and culture [5][6] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the market, citing strong fundamentals and a favorable environment for growth [13] - The company is taking a prudent approach to long-term guidance, evaluating market conditions and performance regularly [13] Other Important Information - The integration process for Retina Consultants of America is progressing well, with a focus on capital investment and synergy realization [46] - The company is committed to investing approximately $600 million in CapEx, primarily in technology and infrastructure [73] Q&A Session Summary Question: What are the key drivers of the company's strong growth this year? - Management highlighted strong utilization trends, growth in specialty product sales, and broad-based results across U.S. businesses as key drivers [10] Question: How does the company view the sustainability of its growth? - Management indicated that while recent performance has outperformed long-term guidance, they remain cautious and will evaluate all moving pieces before making adjustments [13] Question: What is the company's approach to vaccine demand planning? - The company accumulates initial booking expectations from customers to prepare for vaccine shipments, noting that COVID vaccine demand has become more significant due to retail channel distribution [25] Question: How is the company addressing the challenges in the international market? - Management acknowledged the challenges faced in the international segment but expressed optimism for recovery in fiscal year 2026 due to rebounding clinical trial activity [66] Question: What are the company's capital deployment priorities? - The company plans to invest in business growth, strategic M&A, opportunistic share repurchases, and maintain a growing dividend [73]